Immunovant, Inc. (IMVT) Balance Sheet

The sequential decline in cash and total assets indicates that the company is consuming its balance sheet to fund clinical development, with no offsetting revenue growth. The equity base also contracted from $852.6M to $735.4M, driven by widening losses. This trajectory suggests that without additional financing, the company's runway is shortening, though the current cash position still provides a multi-year buffer.

The current ratio, while declining, remains exceptionally high, indicating that Immunovant has ample short-term assets to cover liabilities. Cash and equivalents constitute 94% of total assets, underscoring a highly liquid balance sheet. However, the quarterly cash burn of approximately $124M implies a runway of roughly 6-7 quarters, which may necessitate capital raises before late 2028 if burn continues to escalate.

The negligible fixed asset base and absence of goodwill indicate that Immunovant's value lies in its intellectual property and clinical pipeline rather than tangible assets. This structure reduces capital intensity but also means the balance sheet provides little collateral for debt financing. The minimal PPE also suggests that the company outsources manufacturing and relies on partnerships, which may limit operational flexibility.

The growing accumulated deficit is a direct result of sustained R&D investment without commensurate revenue. Stock-based compensation, while non-cash, dilutes existing shareholders and increases the share count, potentially pressuring future EPS. The equity base remains positive at $735.4M, but the trend suggests that continued losses will erode equity unless the company achieves commercial success or raises additional capital.

The absence of deferred revenue or unearned revenue suggests that Immunovant has not yet established a recurring revenue stream from its commercial product. The initial revenue of $7.1M in 2027Q1 is nascent and may not provide reliable forward indicators. Investors should monitor prescription trends and reimbursement dynamics, as the balance sheet offers no contractual visibility into future sales.